| 2018-05-16 |
1 |
Complaint |
follow-on patents, U.S. Patent Nos. 6,294,197 (“the ‘197
Patent”) and 6,395,728 (the ‘728 Patent), which…for Exforge: the ‘578 Patent; the ‘197 Patent; and the ‘728 Patent. The ‘578 Patent,
which disclosed and…the ‘578
Patent expired on September 21, 2012. Neither the ‘197 Patent nor the ‘728 Patent
10
As … the
’728 Patent, and is therefore prior art to the ‘728 Patent. The ‘904 Prior Art Patent is
titled…exclusivities associated with U.S. Patent No.
5,399,578 (“the ‘578 Patent”), which covered the active ingredient |
External link to document |
| 2019-03-26 |
139 |
Amended Complaint |
5,399,578
(the ‘578 Patent); U.S. Patent No. 6,294,197 (the ‘197 Patent); and U.S. Patent No. 6,395,728
(the…
Exforge: the ‘578 Patent, the ‘197 Patent, and the ‘728 Patent. The ‘578 Patent, which disclosed
and… the ’728 Patent, and is therefore prior art to the ‘728 Patent. The
‘904 Prior Art Patent is titled …below) to
three patents that Novartis had listed in the FDA’s “Orange Book”: U.S. Patent No. 5,399,578
…the ‘728 Patent). Par and Synthon filed paragraph III certifications to the ‘578 Patent, agreeing
that |
External link to document |
| 2019-08-15 |
193 |
Memorandum & Opinion |
certain follow-on patents (U.S. Patent Nos. 6,294,197 ("the '197 Patent") and 6,395,728…Novartis'
patents. Novartis owned U.S. Patent No. 5,399,578 ("the '578 patent), which covered…, 4, 77. The validity of this patent was not challenged. The patent expired on March 21,
20_12, and… to the patent
holder, among others, and describe the basis for its position that the patent at issue…, "Novartis"), nearing the end of one patent covering their prescription drug, Exforge, a
blood |
External link to document |
| 2022-01-11 |
412 |
Memorandum of Law in Support of Motion |
likely invalidation of their
pivotal . . . 6,395,728 patent[].” Id. at -059. On April 30, 2007, Novartis…likely invalidation of their pivotal . . . 6,395,728 patent[].” Ex. 25, NPC_01520380, at -380
(evaluating…Exforge—the ’197 Patent, the
’728 Patent, and U.S. Patent No. 5,399,578 (“the ’578 Patent”). Ex. 11,5 NPC… likely to win the patent litigation. A patent win would preserve the entire patent term (until
July … not refer to the ’197 Patent by its patent number, but it identified a patent with an
expiration date |
External link to document |
| 2018-07-18 |
47 |
Amended Complaint |
follow-on patents, U.S. Patent Nos. 6,294,197 (the
“‘197 Patent”) and 6,395,728 (the “‘728 Patent”), which…
Exforge: the ‘578 Patent; the ‘197 Patent; and the ‘728 Patent. The ‘578 Patent, which disclosed
and… the ‘578 Patent expired on September 21,
2012. Neither the ‘197 Patent nor the ‘728 Patent afforded … the ’728 Patent, and is therefore prior
art to the ‘728 Patent. The ‘904 Prior Art Patent is titled …exclusivities
associated with U.S. Patent No. 5,399,578 (the “‘578 Patent”), which covered the active ingredient |
External link to document |
| 2023-02-23 |
604 |
Memorandum of Law in Support of Motion |
licensed patents: the 5,399,578, 6,294,197 and 6,395,728
patents. As to the 5,399,578 patent, Class Counsel… Counsel next analyzed
Novartis’s 6,294,197 and 6,395,728 patents, as well as Par’s generic product, …
context of the intersection of antitrust law, patent law, drug manufacturing, and Hatch-Waxman
drug…when Par, and other generics, would have won a
patent challenge, launched generic Exforge without a license…Cipro, because of the then-emerging “scope-of-the-
patent” test. See Ark. Carpenters Health & Welfare |
External link to document |
